Short‐term fully closed‐loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes
We evaluated the efficacy and safety of short‐term fully closed‐loop insulin delivery using faster versus standard insulin aspart in type 2 diabetes. Fifteen adults with insulin‐treated type 2 diabetes underwent 22 hours of closed‐loop insulin delivery with either faster or standard insulin aspart i...
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2019-12, Vol.21 (12), p.2718-2722 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2722 |
|---|---|
| container_issue | 12 |
| container_start_page | 2718 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 21 |
| creator | Bally, Lia Herzig, David Ruan, Yue Wilinska, Malgorzata E. Semmo, Mariam Vogt, Andreas Wertli, Maria M. Vogt, Bruno Stettler, Christoph Hovorka, Roman |
| description | We evaluated the efficacy and safety of short‐term fully closed‐loop insulin delivery using faster versus standard insulin aspart in type 2 diabetes. Fifteen adults with insulin‐treated type 2 diabetes underwent 22 hours of closed‐loop insulin delivery with either faster or standard insulin aspart in a double‐blind randomized crossover design. Basal‐bolus regimen was replaced by model predictive control algorithm‐directed insulin delivery based on sensor glucose levels. The primary outcome was time with plasma glucose in target range (5.6–10.0 mmol/L) and did not differ between treatments (mean difference [95% CI] 3.3% [−8.2; 1.7], P = 0.17). Mean glucose and glucose variability were comparable, as was time spent below and above target range. Hypoglycaemia ( |
| doi_str_mv | 10.1111/dom.13861 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2282514143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2282514143</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-3a6d4e2e97082f66c979debbe32264daab492129e2498590b5b8e386bfe26d113</originalsourceid><addsrcrecordid>eNp1kb1uFTEQhS1EREKg4AWQJRooNrHHvr52icKvlCgFUFve9Sxx5F0v9i7RdlTUPCNPgslNUkTKNDOa-eZoNIeQF5wd8RrHPg1HXGjFH5EDLpVouAD1-LqGRhsG--RpKZeMMSn09gnZF3UimRIH5PeXi5Tnv7_-zJgH2i8xrrSLqaCvvZjSRMNYlhhG6jGGn5hXupQwfqe9K3XlburK5PJMuzTUjJ5ehfmCltmN3mV_n6rVvE5IgfrgWpyxPCN7vYsFn9_kQ_Ltw_uvJ5-a0_OPn0_enjad0Jo3wikvEdBsmYZeqc5sjce2RQGgpHeulQY4GARp9MawdtNqrI9pewTlOReH5PVOd8rpx4JltkMoHcboRkxLsQAaNlxyKSr66h56mZY81uss1P9xbgzISr3ZUV1OpWTs7ZTD4PJqObP_zbHVHHttTmVf3igu7YD-jrx1owLHO-AqRFwfVrLvzs92kv8Av5mcUQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2314119924</pqid></control><display><type>article</type><title>Short‐term fully closed‐loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes</title><source>Wiley Online Library All Journals</source><creator>Bally, Lia ; Herzig, David ; Ruan, Yue ; Wilinska, Malgorzata E. ; Semmo, Mariam ; Vogt, Andreas ; Wertli, Maria M. ; Vogt, Bruno ; Stettler, Christoph ; Hovorka, Roman</creator><creatorcontrib>Bally, Lia ; Herzig, David ; Ruan, Yue ; Wilinska, Malgorzata E. ; Semmo, Mariam ; Vogt, Andreas ; Wertli, Maria M. ; Vogt, Bruno ; Stettler, Christoph ; Hovorka, Roman</creatorcontrib><description>We evaluated the efficacy and safety of short‐term fully closed‐loop insulin delivery using faster versus standard insulin aspart in type 2 diabetes. Fifteen adults with insulin‐treated type 2 diabetes underwent 22 hours of closed‐loop insulin delivery with either faster or standard insulin aspart in a double‐blind randomized crossover design. Basal‐bolus regimen was replaced by model predictive control algorithm‐directed insulin delivery based on sensor glucose levels. The primary outcome was time with plasma glucose in target range (5.6–10.0 mmol/L) and did not differ between treatments (mean difference [95% CI] 3.3% [−8.2; 1.7], P = 0.17). Mean glucose and glucose variability were comparable, as was time spent below and above target range. Hypoglycaemia (<3.5 mmol/L) occurred once with faster insulin aspart and twice with standard insulin aspart. Mean total insulin dose was higher with faster insulin aspart (mean difference [95% CI] 3.7 U [0.7; 6.8], P = 0.021). No episodes of severe hypoglycaemia or other serious adverse events occurred. In conclusion, short‐term fully closed‐loop in type 2 diabetes may require higher dose of faster insulin aspart compared with standard insulin aspart to achieve comparable glucose control.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.13861</identifier><identifier>PMID: 31464063</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>antidiabetic drug ; Antidiabetics ; artificial pancreas ; closed‐loop system ; Control algorithms ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Glucose ; Hypoglycemia ; Insulin ; insulin analogues ; insulin pump therapy ; randomized trial ; type 2 diabetes</subject><ispartof>Diabetes, obesity & metabolism, 2019-12, Vol.21 (12), p.2718-2722</ispartof><rights>2019 John Wiley & Sons Ltd</rights><rights>2019 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-3a6d4e2e97082f66c979debbe32264daab492129e2498590b5b8e386bfe26d113</citedby><cites>FETCH-LOGICAL-c3881-3a6d4e2e97082f66c979debbe32264daab492129e2498590b5b8e386bfe26d113</cites><orcidid>0000-0003-3498-2543 ; 0000-0003-1993-7672 ; 0000-0001-6347-0198</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.13861$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.13861$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31464063$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bally, Lia</creatorcontrib><creatorcontrib>Herzig, David</creatorcontrib><creatorcontrib>Ruan, Yue</creatorcontrib><creatorcontrib>Wilinska, Malgorzata E.</creatorcontrib><creatorcontrib>Semmo, Mariam</creatorcontrib><creatorcontrib>Vogt, Andreas</creatorcontrib><creatorcontrib>Wertli, Maria M.</creatorcontrib><creatorcontrib>Vogt, Bruno</creatorcontrib><creatorcontrib>Stettler, Christoph</creatorcontrib><creatorcontrib>Hovorka, Roman</creatorcontrib><title>Short‐term fully closed‐loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>We evaluated the efficacy and safety of short‐term fully closed‐loop insulin delivery using faster versus standard insulin aspart in type 2 diabetes. Fifteen adults with insulin‐treated type 2 diabetes underwent 22 hours of closed‐loop insulin delivery with either faster or standard insulin aspart in a double‐blind randomized crossover design. Basal‐bolus regimen was replaced by model predictive control algorithm‐directed insulin delivery based on sensor glucose levels. The primary outcome was time with plasma glucose in target range (5.6–10.0 mmol/L) and did not differ between treatments (mean difference [95% CI] 3.3% [−8.2; 1.7], P = 0.17). Mean glucose and glucose variability were comparable, as was time spent below and above target range. Hypoglycaemia (<3.5 mmol/L) occurred once with faster insulin aspart and twice with standard insulin aspart. Mean total insulin dose was higher with faster insulin aspart (mean difference [95% CI] 3.7 U [0.7; 6.8], P = 0.021). No episodes of severe hypoglycaemia or other serious adverse events occurred. In conclusion, short‐term fully closed‐loop in type 2 diabetes may require higher dose of faster insulin aspart compared with standard insulin aspart to achieve comparable glucose control.</description><subject>antidiabetic drug</subject><subject>Antidiabetics</subject><subject>artificial pancreas</subject><subject>closed‐loop system</subject><subject>Control algorithms</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Glucose</subject><subject>Hypoglycemia</subject><subject>Insulin</subject><subject>insulin analogues</subject><subject>insulin pump therapy</subject><subject>randomized trial</subject><subject>type 2 diabetes</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kb1uFTEQhS1EREKg4AWQJRooNrHHvr52icKvlCgFUFve9Sxx5F0v9i7RdlTUPCNPgslNUkTKNDOa-eZoNIeQF5wd8RrHPg1HXGjFH5EDLpVouAD1-LqGRhsG--RpKZeMMSn09gnZF3UimRIH5PeXi5Tnv7_-zJgH2i8xrrSLqaCvvZjSRMNYlhhG6jGGn5hXupQwfqe9K3XlburK5PJMuzTUjJ5ehfmCltmN3mV_n6rVvE5IgfrgWpyxPCN7vYsFn9_kQ_Ltw_uvJ5-a0_OPn0_enjad0Jo3wikvEdBsmYZeqc5sjce2RQGgpHeulQY4GARp9MawdtNqrI9pewTlOReH5PVOd8rpx4JltkMoHcboRkxLsQAaNlxyKSr66h56mZY81uss1P9xbgzISr3ZUV1OpWTs7ZTD4PJqObP_zbHVHHttTmVf3igu7YD-jrx1owLHO-AqRFwfVrLvzs92kv8Av5mcUQ</recordid><startdate>201912</startdate><enddate>201912</enddate><creator>Bally, Lia</creator><creator>Herzig, David</creator><creator>Ruan, Yue</creator><creator>Wilinska, Malgorzata E.</creator><creator>Semmo, Mariam</creator><creator>Vogt, Andreas</creator><creator>Wertli, Maria M.</creator><creator>Vogt, Bruno</creator><creator>Stettler, Christoph</creator><creator>Hovorka, Roman</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3498-2543</orcidid><orcidid>https://orcid.org/0000-0003-1993-7672</orcidid><orcidid>https://orcid.org/0000-0001-6347-0198</orcidid></search><sort><creationdate>201912</creationdate><title>Short‐term fully closed‐loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes</title><author>Bally, Lia ; Herzig, David ; Ruan, Yue ; Wilinska, Malgorzata E. ; Semmo, Mariam ; Vogt, Andreas ; Wertli, Maria M. ; Vogt, Bruno ; Stettler, Christoph ; Hovorka, Roman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-3a6d4e2e97082f66c979debbe32264daab492129e2498590b5b8e386bfe26d113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>antidiabetic drug</topic><topic>Antidiabetics</topic><topic>artificial pancreas</topic><topic>closed‐loop system</topic><topic>Control algorithms</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Glucose</topic><topic>Hypoglycemia</topic><topic>Insulin</topic><topic>insulin analogues</topic><topic>insulin pump therapy</topic><topic>randomized trial</topic><topic>type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bally, Lia</creatorcontrib><creatorcontrib>Herzig, David</creatorcontrib><creatorcontrib>Ruan, Yue</creatorcontrib><creatorcontrib>Wilinska, Malgorzata E.</creatorcontrib><creatorcontrib>Semmo, Mariam</creatorcontrib><creatorcontrib>Vogt, Andreas</creatorcontrib><creatorcontrib>Wertli, Maria M.</creatorcontrib><creatorcontrib>Vogt, Bruno</creatorcontrib><creatorcontrib>Stettler, Christoph</creatorcontrib><creatorcontrib>Hovorka, Roman</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bally, Lia</au><au>Herzig, David</au><au>Ruan, Yue</au><au>Wilinska, Malgorzata E.</au><au>Semmo, Mariam</au><au>Vogt, Andreas</au><au>Wertli, Maria M.</au><au>Vogt, Bruno</au><au>Stettler, Christoph</au><au>Hovorka, Roman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short‐term fully closed‐loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2019-12</date><risdate>2019</risdate><volume>21</volume><issue>12</issue><spage>2718</spage><epage>2722</epage><pages>2718-2722</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><abstract>We evaluated the efficacy and safety of short‐term fully closed‐loop insulin delivery using faster versus standard insulin aspart in type 2 diabetes. Fifteen adults with insulin‐treated type 2 diabetes underwent 22 hours of closed‐loop insulin delivery with either faster or standard insulin aspart in a double‐blind randomized crossover design. Basal‐bolus regimen was replaced by model predictive control algorithm‐directed insulin delivery based on sensor glucose levels. The primary outcome was time with plasma glucose in target range (5.6–10.0 mmol/L) and did not differ between treatments (mean difference [95% CI] 3.3% [−8.2; 1.7], P = 0.17). Mean glucose and glucose variability were comparable, as was time spent below and above target range. Hypoglycaemia (<3.5 mmol/L) occurred once with faster insulin aspart and twice with standard insulin aspart. Mean total insulin dose was higher with faster insulin aspart (mean difference [95% CI] 3.7 U [0.7; 6.8], P = 0.021). No episodes of severe hypoglycaemia or other serious adverse events occurred. In conclusion, short‐term fully closed‐loop in type 2 diabetes may require higher dose of faster insulin aspart compared with standard insulin aspart to achieve comparable glucose control.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>31464063</pmid><doi>10.1111/dom.13861</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-3498-2543</orcidid><orcidid>https://orcid.org/0000-0003-1993-7672</orcidid><orcidid>https://orcid.org/0000-0001-6347-0198</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2019-12, Vol.21 (12), p.2718-2722 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2282514143 |
| source | Wiley Online Library All Journals |
| subjects | antidiabetic drug Antidiabetics artificial pancreas closed‐loop system Control algorithms Diabetes Diabetes mellitus (non-insulin dependent) Glucose Hypoglycemia Insulin insulin analogues insulin pump therapy randomized trial type 2 diabetes |
| title | Short‐term fully closed‐loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T05%3A05%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short%E2%80%90term%20fully%20closed%E2%80%90loop%20insulin%20delivery%20using%20faster%20insulin%20aspart%20compared%20with%20standard%20insulin%20aspart%20in%20type%202%20diabetes&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Bally,%20Lia&rft.date=2019-12&rft.volume=21&rft.issue=12&rft.spage=2718&rft.epage=2722&rft.pages=2718-2722&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/dom.13861&rft_dat=%3Cproquest_cross%3E2282514143%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2314119924&rft_id=info:pmid/31464063&rfr_iscdi=true |